Topiramate Tablet, Film Coated
Product Images NDC 60760-075

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 60760-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Top (Topiramate 60760 075 60)

Topiramate 25 mg film-coated tablets label displays the product name, strength, dosage form, and quantity of 60 tablets. It shows the National Drug Code (NDC 60760-075-60), Rx number placeholder, and lot and expiration date placeholders. The label includes manufacturer information for Cadila Healthcare Ltd, Ahmedabad, India, and packaging and pharmacy details for St. Mary's Medical Park Pharmacy in Oro Valley, AZ. Storage instructions advise controlled room temperature (15°-30°C).*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 01)

Chemical structure of topiramate, depicting its molecular arrangement with various functional groups including sulfate and multiple methyl groups.*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 02)

A Kaplan-Meier survival curve graph showing cumulative rates for time to first seizure over approximately 500 days, comparing two dosages of topiramate (50 mg/day solid line and 400 mg/day dashed line). The X-axis represents time in days, and the Y-axis shows cumulative rates for time to first seizure, with a p-value of 0.0002 indicating statistical comparison.*

FDA Label Image

Topiramate Tablets Usp (A9eed983 Edf1 4f44 A8ec 568a52f03015 03)

A bar graph showing the change from baseline to double-blind phase in average monthly migraine period rate (± SE) for placebo and three dosages of topiramate (50 mg/day, 100 mg/day, 200 mg/day) across two studies (Study 10 and Study 11). The graph indicates greater reductions in migraine period rate with increasing doses of topiramate compared to placebo, with statistical significance noted using p-values.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.